- Home
- IKT vs EUDA Comparison
IKT vs EUDA Comparison
Compare IKT & EUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- EUDA
- Stock Information
- Founded
- IKT 2008
- EUDA 2021
- Country
- IKT United States
- EUDA Singapore
- Employees
- IKT N/A
- EUDA N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- EUDA Blank Checks
- Sector
- IKT Health Care
- EUDA Finance
- Exchange
- IKT Nasdaq
- EUDA Nasdaq
- Market Cap
- IKT 167.2M
- EUDA 139.3M
- IPO Year
- IKT 2020
- EUDA N/A
- Fundamental
- Price
- IKT $1.90
- EUDA $4.04
- Analyst Decision
- IKT Buy
- EUDA
- Analyst Count
- IKT 2
- EUDA 0
- Target Price
- IKT $8.00
- EUDA N/A
- AVG Volume (30 Days)
- IKT 147.0K
- EUDA 108.0K
- Earning Date
- IKT 05-14-2025
- EUDA 01-01-0001
- Dividend Yield
- IKT N/A
- EUDA N/A
- EPS Growth
- IKT N/A
- EUDA N/A
- EPS
- IKT N/A
- EUDA N/A
- Revenue
- IKT N/A
- EUDA $3,811,496.00
- Revenue This Year
- IKT N/A
- EUDA $66.63
- Revenue Next Year
- IKT N/A
- EUDA $102.75
- P/E Ratio
- IKT N/A
- EUDA N/A
- Revenue Growth
- IKT N/A
- EUDA N/A
- 52 Week Low
- IKT $1.12
- EUDA $1.69
- 52 Week High
- IKT $4.20
- EUDA $6.30
- Technical
- Relative Strength Index (RSI)
- IKT 42.84
- EUDA 56.33
- Support Level
- IKT $1.58
- EUDA $3.80
- Resistance Level
- IKT $2.22
- EUDA $4.04
- Average True Range (ATR)
- IKT 0.22
- EUDA 0.23
- MACD
- IKT 0.00
- EUDA 0.04
- Stochastic Oscillator
- IKT 45.57
- EUDA 88.28
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.